Chief Scientific Officer, Vium
BIOGRAPHY
JUN 26, 2018 9:00 AM PDT
Automated In Vivo Efficacy Assessment in Preclinical Lung Disease Models
Speaker
Event Date & Time
DATE: June 26, 2018
TIME: 09:00AM PDT, 12:00PM EDT
Abstract
Treatments for respiratory diseases represent an enormous, unmet medical need with limited therapies currently approved for use. Despite many compounds demonstrating beneficial effects in animals models, very few translate into successful therapies. To improve translational efficacy of respiratory animal models, researchers are calling for the development of new druggable targets, better biomarkers and the use of more clinically relevant endpoints in preclinical animal studies. This presentation will describe a novel technology platform that allows for non-invasive real-time monitoring of lung function in preclinical studies of respiratory disease and will present several use cases demonstrating how automated longitudinal monitoring provides insight into disease biology in animal models of Idiopathic Pulmonary Fibrosis (IPF) and Pneumonia.
In this webinar you will:
- Review method for automated collection of breathing data and comparison of data collection to traditional techniques
- Demonstrate how automated longitudinal monitoring of breathing provides insight into disease biology in preclinical lung disease models
You May Also Like
DEC 10, 2024 | 9:00 AM
To-date, proteomic analysis has been severely limited in scale and resolution. Analyzing protein samples using an intact, single-molecule approach holds th...
OCT 02, 2024 | 7:30 AM
De novo gene synthesis and protein expression are established technologies that can give access to nearly any target DNA or protein sequence, allowing for engineering of biologics. In this p...
JUN 26, 2018 9:00 AM PDT
Share
Automated In Vivo Efficacy Assessment in Preclinical Lung Disease Models
Loading Comments...